Clinical trials: Adjuvant Treatment
Breast Cancer
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
- Trial name
- NCT00036621
- Testing
- BMS-275291
- Where
- 9 sites in United States
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1…
- Trial name
- NCT07444437
- Testing
- LM103 TILs Injection, PD-1 / PD-L1 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Colorectal Cancer
Tumour Registry Colorectal Cancer
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.
- Trial name
- TKK (NCT00910819)
- Where
- Germany
- Volunteers
- 7,000 people
- Sponsor
- iOMEDICO AG
Breast Cancer
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer.
- Trial name
- NCT01152398
- Testing
- MVA-BN-HER2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bavarian Nordic
Pancreatic Neoplasms, Digestive System Neoplasms
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared…
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- apact (NCT01964430)
- Testing
- nab-Paclitaxel, Gemcitabine
- Where
- 341 sites in United States, Australia and 19 more
- Volunteers
- 866 people
- Sponsor
- Celgene
Low-Risk, Early Stage Breast Cancer
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy.
- Trial name
- NCT07629206
- Testing
- Cryoablation
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- IceCure Medical Ltd.
Early Breast Cancer, Skin Condition
An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
The goal of this European observational study (Frane, Spain, italy, Spain and Greece) is to describe the quality of life related to dermatological toxicities, in adult women patients with Early Breast Cancer (EBC), treated with…
- Conditions
- Early Breast Cancer, Skin Condition, Quality of Life
- Trial name
- BCARE (NCT06690489)
- Where
- 9 sites in France, Greece and 2 more
- Volunteers
- 155 people
- Sponsor
- Pierre Fabre Medicament
Radius Fractures
Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures
To evaluate the safety of rhBMP-2/CPM administered to subjects presenting with closed distal radius fractures. The key safety variables comprising this assessment are: 1) incidence of delayed union; 2) median time to fracture…
- Trial name
- NCT00161629
- Testing
- rhBMP-2/CPM
- Where
- 7 sites in Finland, France
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but…
- Trial name
- NCT06440967
- Testing
- Fezolinetant, Tamoxifen, Aromatase inhibitor
- Where
- 110 sites in Canada, Czechia and 9 more
- Volunteers
- 982 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Glioblastoma Multiforme
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment…
- Trial name
- NCT00394628
- Testing
- AQ4N, Temozolomide, Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novacea
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Prostate Cancer
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia
The objective of this study was to describe treatment patterns of leuprorelin over 2 years using an intermittent, adjuvant regimen in participants with advanced prostate cancer (PCa)
- Trial name
- NCT01320735
- Volunteers
- 300 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cancer, Liver Cancer
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Primary Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATHWAY (NCT00568308)
- Testing
- PI-88
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Progen Pharmaceuticals
Lung Cancer
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients…
- Trial name
- ECHO (NCT07593248)
- Where
- 14 sites in China
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Breast Cancer
Breast Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- OPAL (NCT03417115)
- Where
- Germany
- Volunteers
- 6,150 people
- Sponsor
- iOMEDICO AG
Early Breast Cancer
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
- Trial name
- NCT01155063
- Testing
- Aromasin (exemestane)
- Volunteers
- 89 people
- Sponsor
- Pfizer
Breast Neoplasms
A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse
The purpose of this study is to evaluate if a maximum tolerated dose (MTD) can be obtained following 2 administrations of the MAG-Tn3 + AS15 cancer vaccine when administered at doses of 30 µg, 100 µg or 300 µg IM every three…
- Trial name
- MAGTRIVACSEIN (NCT02364492)
- Testing
- MAG-TN3 + AS15
- Where
- 5 sites in France
- Volunteers
- 20 people
- Sponsor
- Institut Pasteur
Bacterial Infections, Treatment of Fungal Infections, Candidiasis
Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial Infections
The medical device It is indicated to promote the re-epithelialization processes of the vaginal mucosa, in the prevention of vaginal conditions of bacterial and fungal origin, and as an adjuvant in their treatment.
- Trial name
- NCT07367295
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Innate srl
Non-small Cell Lung Cancer
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA…
- Trial name
- ICAPE (NCT02044328)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Melanoma
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of…
- Trial name
- NCT03897881
- Testing
- mRNA-4157, Pembrolizumab
- Where
- 23 sites in United States, Australia
- Volunteers
- 267 people
- Sponsor
- ModernaTX, Inc.